ArticleViruses2022
In Vitro and Pre-Clinical Evaluation of Locally Isolated Phages, vB_Pae_SMP1 and vB_Pae_SMP5, Formulated as Hydrogels against Carbapenem-Resistant
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence.MicrobiologyOpen · 2026Review
- Characterization and evaluation of the efficacy of phage E21 therapy in a wound animal model of biofilm-associated Pseudomonas aeruginosa infection.Scientific reports · 2026Article
- Revolutionizing diabetic foot ulcer treatment: phage therapy as a next-generation antimicrobial approach- a review on breaking the cycle of resistance.Journal of diabetes and metabolic disorders · 2025Review
- Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage.Applied microbiology and biotechnology · 2025Article
- In vitro, genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.Therapeutic delivery · 2025Review
- Novel delivery systems for phages and lysins in the topical management of wound infections: a narrative review.Frontiers in microbiology · 2025Review
- Systematic bacteriophage selection for the lysis of multipleFrontiers in cellular and infection microbiology · 2025Article
- Bacteriophages againstFrontiers in bioengineering and biotechnology · 2025Review
- Insights into the Preparation of and Evaluation of the Bactericidal Effects of Phage-Based Hydrogels.International journal of molecular sciences · 2024Review
- Review
- Genomic characterization, in vitro, and preclinical evaluation of two microencapsulated lytic phages VB_ST_E15 and VB_ST_SPNIS2 against clinical multidrug-resistant Salmonella serovars.Annals of clinical microbiology and antimicrobials · 2024Article
- Bacteriophage-mediated approaches for biofilm control.Frontiers in cellular and infection microbiology · 2024Review
- Novel Antiviral Agents: Synthesis, Molecular Modelling Studies and Biological Investigation.Viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inadequate therapeutic opportunities associated with carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.